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Background: Macrovascular diseases (MVD) in type 2 diabetes mellitus (T2DM) are often considered all together,
without discriminating the areas involved. The aim of our study was to analyse MVD prevalence in a large population
of T2DM patients by dividing the cases into subgroups according to MVD sites (NMVD, no MVD; NSCS, non-significant
carotid stenosis; CBVD, cerebrovascular disease; CAD, coronary artery disease; PAD, peripheral artery disease; PVD,
polyvascular disease) and studying the anthropometric, clinical and laboratory parameters in each group.
Methods: A diabetic outpatient cohort (n = 1199) was retrospectively studied. Demographic, clinical and laboratory
parameters were included in analyses. A thorough cardiovascular history as documented by previous medical records
(including medical and hospital records) and vascular laboratory studies (including standardised electrocardiogram,
echocardiogram, provocative tests for cardiac ischaemia, ankle/brachial index, duplex ultrasonography of the carotid
and lower limbs and, in selected cases, computed tomography angiography, carotid and peripheral arteriography and
evaluation of transcutaneous oxygen pressure), was collected for all of the patients. Standardised procedures were
used to assess microvascular complications as well as metabolic syndrome (Mets).
Results: The unadjusted MVD prevalence was 46.4% among the participants. The majority of patients with MVD were
in the PVD group. In the multivariate analysis, age, male sex and diabetes duration were independent risk factors for
PAD and PVD (P < 0.01). A low HDL-C value was an independent risk factor in the CAD and PVD groups (P = 0.03). Very
high frequencies of MetS were observed in the PAD and PVD groups (94.9 and 95.7% respectively). The most MetS
diagnostic criteria were recorded among members of the CAD group (all or all-1 criteria were present in 73% of
patients). The average age in the CAD group (64.5 y) was comparable to that of the NMVD group. Microvascular
complications were more frequent in the PAD and PVD patients.
Conclusion: Phenotypic heterogeneity is associated with different macrovascular complications in T2DM patients. These
findings might have clinical implications for developing diagnostic and therapeutic strategies targeting type 2 diabetes.
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Cardiovascular complications are the leading cause of mor-
bidity and mortality among patients with type 2 diabetes,
and cardiovascular disease (CVD) risk is 2- to 8-fold higher
in the diabetic population than it is in non-diabetic indivi-
duals of a similar age, sex and ethnicity [1,2]. Furthermore,
macrovascular complications are the largest contributor to
the direct and indirect costs of diabetes [3]. However, when* Correspondence: gpapa_98@yahoo.com
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patient population is lumped together as a heterogeneous
group with CVD, without separation into subgroups ac-
cording to the macrovascular disease type. Furthermore
multiple vascular sites are often simultaneously involved in
type 2 diabetic patients, which contributes to the highest
cardiovascular risk in this population. To the best of our
knowledge, no extensive clinical studies of type 2 diabetic
subjects have stratified patients according to their macro-
vascular complications. The aim of our retrospective study
was to evaluate macrovascular disease in a large cohort of
type 2 diabetic adults by dividing the subjects into severald. This is an Open Access article distributed under the terms of the Creative
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iginal work is properly cited.
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volved. We also studied differences between these sub-
groups in their anthropometric, clinical and laboratory
characteristics, as well as their MetS prevalence/severity.
Methods
Subjects
In this observational, cross-sectional survey, we studied
1199 subjects with type 2 diabetes who had been referred
to us by general practitioners or other specialists for dia-
betes management and/or chronic complication assess-
ment between January 1, 2008 and January 1, 2011. The
subjects were divided into 6 subgroups: NMVD, no
macrovascular disease; NSCS, non-significant carotid ste-
nosis; CBVD, cerebrovascular disease; CAD, coronary
artery disease; PAD, peripheral artery disease; and PVD,
polyvascular disease. The data were collected from a diag-
nostic Day-Hospital in our centre and were retrospectively
analysed. The exclusion criteria were as follows: acute ill-
nesses, advanced renal disease (creatinine clearance ≤15
ml/min or dialysis), chronic active hepatitis (liver transa-
minases ≥2 times higher than the normal range and/or
positive viral hepatitis B or C serology), or glucocorticoid
therapy. The local ethics committee approved the study.
Clinical and laboratory measurements
Body weight was measured in light clothing without
shoes to the nearest half kilogram. Height was measured
to the nearest half centimetre. Body mass index (BMI)
was calculated as the weight (kg) divided by height2 (m).
Waist circumference (WC, to the nearest half centimetre)
was measured in the standing position at the umbilicus.
Arterial blood pressure was taken with a standard mer-
cury blood pressure meter. Three blood pressure readings
were obtained at 1 min intervals, and the systolic and dia-
stolic pressure readings were averaged and used for the
analysis. Venous blood was drawn in the morning at ward
admission after a 10–12 h overnight fast. All of the bio-
chemical parameters were evaluated with standard labora-
tory procedures. All of the patients were tested for viral
hepatitis B and C. LDL cholesterol was calculated by the
Friedewald formula except when the serum triglyceride
concentration was >400 mg/dL. HbA1c was measured by
high-performance liquid chromatography (HPLC); the
upper normality limit for the laboratory was 5.9%. A daily
glycaemic profile with 6 finger-prick tests (One Touch
Ultra, LifeScan, Milpitas, California, USA) was also ob-
tained from all of the patients. Metabolic Syndrome
(MetS) was diagnosed using the AHA-NHLBI criteria [4],
by the presence of diabetes and ≥2 of the following com-
ponents: 1) WC >102 cm in men and >88 cm in women;
2) triglycerides >1.7 mmol/L (150 mg/dL) or fibrate/fish
oil users; 3) HDL <1.0 mmol/L (40 mg/dL) in men and
<1.29 mmol/L (50 mg/dL) in women; and 4) bloodpressure ≥130/85 mmHg or receiving blood pressure re-
duction treatment.
Macrovascular complication evaluation
A thorough cardiovascular history, as documented by pre-
vious medical records (including medical and hospital
records) and vascular laboratory studies (including standar-
dised electrocardiogram, echocardiogram, ankle/brachial
index, duplex ultrasonography (DUS) of the carotid and
lower limbs and provocative tests for cardiac ischaemia),
was collected for all of the patients.
Non-significant carotid stenosis (NSSC) diagnosis
Asymptomatic patients with 50-69% carotid stenosis in
any section as detected by DUS were diagnosed with
NSSC.
Cerebrovascular disease (CBVD) diagnosis
Patients with a history of TIA, previous stroke (as con-
firmed by CT/MRI brain scan), or previous significant/
symptomatic carotid stenosis (patients had undergone
surgical or endoluminal interventions) were diagnosed
with CBVD. However, asymptomatic patients with signifi-
cant stenosis (≥70% in any section as detected by DUS
and confirmed by computed tomography angiography
(CTA)) were also included in this group. Patients who
were undergoing interventional procedures were sent di-
rectly for a carotid arteriography.
Coronary artery disease (CAD) diagnosis
We included in this group all of the patients with previous
acute coronary sindromes (ACS) diagnoses (STEMI,
NSTEMI, unstable angina) whether or not they had endo-
luminal or surgical revascularisation procedures. We also
included those patients with ischaemic heart disease and
stable angina. All of the patients were subjected to cardiac
examination, ECG and echocardiogram to confirm the
previous diagnosis. Patients with ECG abnormalities or
symptoms that were suggestive of ischaemia and/or with
provocative tests suspected for myocardial ischaemia were
sent for a coronary angiography to confirm the diagnosis
or endoluminal treatment.
Peripheral artery disease (PAD) diagnosis
Patients who had endoluminal or surgical revascularisation
interventional procedures, had previous amputations, or
had been diagnosed with ischaemic ulcers were diagnosed
with PAD. All of the symptomatic patients (Fontaine’s
classification stage II-IV) who were confirmed by ABI and
DUS were diagnosed with PAD. Asymptomatic patients
with an ABI <0.9 who had significant stenosis or occlu-
sions as determined by DUS (and confirmed by peripheral
CTA) were also included in the PAD group. Patients with
suspected critical limb ischaemia were evaluated by
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were <30 mmHg, then the patients were referred to angi-
ography to perform endoluminal procedures.
Polyvascular disease (PVD) diagnosis
When two or more of the above conditions were present
at the same time, the patients were diagnosed with PVD.
No macrovascular disease (NMVD) diagnosis
Patients who did not meet the criteria above were not
considered to have cardiovascular disease.
Microvascular complication evaluations
Microvascular complications were evaluated using fundus
oculi and/or fluorescence angiography to assess retino-
pathy, urinary albumin excretion and eGFR calculation to
assess nephropathy, and the 10g monofilament test and
vibration perception threshold analysis to assess peri-
pheral neuropathy. Microalbuminuria was defined as uri-
nary albumin excretion between 30 and 299 mg/day on at
least 2 of 3 occasions. The eGFR was calculated using the
MDRD formula [estimated GFR (mL/m/1.73 m2) = 186 ×
creatinine (mg/dl)-1.154 × age (yy)-0.203 × 0.742 (if female) ×
1.210 (if of black ethnicity)] [5]. Diabetic retinopathy was
defined as any diabetes-linked retinal injury. Diabetic per-
ipheral neuropathy was diagnosed based on neuropathic
symptoms, insensitivity to a 10g monofilament and an ab-
normal vibration perception threshold.
Statistical analysis
The data were tested for normalcy using the Kolmogorov-
Smirnov test, which indicated a non-Gaussian distribution
for all continuous variables; therefore, the results were
reported as a median value and an interquartile range
(IQR, 25th-75th quartiles). Univariate analysis was per-
formed with the non-parametric Kruskal-Wallis test and
Dunn’s multiple comparison post-hoc test to compare
each of the continuous variables of interest among the
macrovascular groups. The qualitative variable data were
expressed as frequencies, and the groups were compared
using the chi-square test. Multivariate logistic regression
analysis was used to determine whether traditional cardio-
vascular risk factors (sex, age, smoking status, diabetes
duration, WC, SBP, DBP, LDL-C, HDL-C, triglyceride
levels, HbA1c, FPG, use of antihypertensive and lipid-
lowering drugs and the presence of AHA/NHLBI-defined
metabolic syndrome) were associated with prevalent CVD
(dependent variable, MVD; reference group, NMVD), and
the results were expressed as odds ratios (ORs) ± 95% CI.
The ORs were calculated using exponential logistic regres-
sion coefficients. A p-value of less than 0.05 was consid-
ered to be statistically significant. All of the analyses were
performed with SPSS version 17 (Chicago, IL, USA) and
Prism software (GraphPad, USA).Results
Clinical and biochemical patient characteristics are pre-
sented in Table 1. In total, 643 (53.6%) patients had no
evidence of macrovascular disease, and the remaining 556
(46.4%) had MVD (see Figure 1, panel A). There were
12.4% of the MVD patients who were classified as NSCS,
14.6% as CBVD, 16% as CAD, 10.6% as PAD, and 46.4% as
PVD (Figure 1, panel B).
Univariate analyses
Macrovascular disease, anthropometric and clinical data
Patients with CBVD, PAD and PVD were older than were
patients in the other groups. CAD patients were similar in
age to those without complications and to those in the
NSCS group. Male patients were more numerous in CAD,
PAD and PVD groups, whereas female patients were more
numerous in the other groups.
Diabetes duration was significantly greater in the PAD
and PVD patients. BMI was significantly lower in the PVD
group compared to the NMVD and CAD groups.
Macrovascular disease and metabolic parameters
We found no differences in the metabolic parameters
among the 6 subgroups. The HbA1c levels, FPG levels,
post-prandial glucose levels, and Δpre-postprandial plasma
glucose levels were comparable among all of the groups.
All of the data were outside of the normal ranges because
the patients had poor glycaemic control at this first obser-
vation in our centre.
Macrovascular disease and lipoprotein profile
The extensive use of statins across all of the groups
strongly influenced the lipid profile in our patients. The
total cholesterol levels were higher in patients without
complications or with NSCS compared with CAD or PVD
patients, and the LDL-C values followed the same trend.
HDL-C was significantly lower in the CAD and PVD
patients compared to those in the NMVD and CBVD
groups. No significant differences in the triglyceride values
were found among the groups.
Macrovascular disease and MetS
As expected, metabolic syndrome prevalence was signifi-
cantly greater in patients who belonged to the macrovas-
cular groups than in patients who did not have
complications. The highest prevalence was recorded in the
PAD (94.9%) and PVD (95.7%) patients. The simultaneous
presence of 3 or 4 diagnostic MetS criteria (indicating
MetS severity) was more frequent in CAD patients (73%)
(Figure 2).
Macrovascular disease and microvascular complications
Microvascular complications (diabetic retinopathy, diabetic
nephropathy and diabetic neuropathy) were significantly
Table 1 Clinical and metabolic patient variables (all of the patients and grouped according to macro-vascular involvement)
Variables All NMVD (I) NSCS (II) CBVD (III) CAD (IV) PAD (V) PVD (VI) p differences among
the groupsa
N patients (%) 1199 643 (53.6) 69 (5.7) 81 (6.8) 89 (7.4) 59 (4.9) 258 (21.5) _
Age (yy) 67 (58–75) 63 (55–72) 66 (59–71) 73 (66–79) 65 (55–75) 72 (65–76) 73 (67–78) I≠III,V,VI***, II≠III**,VI*** III≠IV***,
IV≠V*,VI***
Sex %M 49.5 45.3 39.1 37 58.4 61 61.2 ***
DM2 duration (yy) 12 (6–20) 10 (5–18) 10 (5–15.5) 12.5 (7–20) 14 (6–20) 20 (10–30) 20 (10–28.3) I≠V,VI***, II≠V,VI***, III≠VI*,
IV≠VI**
Weight (Kg) 80 (69.5-92.7) 81 (71.1-94.4) 80.1 (67.3-93.8) 74.6 (65.1-85.5) 85.7 (74.4-98.6) 75.2 (67–90) 76.5 (65.4-87.8) I≠III,VI**, III≠IV***, IV≠VI**
BMI (Kg/m2) 31.1 (27.6-35.5) 31.5 (28.1-36.4) 31.5 (26.5-36.6) 29.7 (27.1-33.6) 32.2 (27.6-37) 30.3 (26.3-34.9) 30 (26.3-33.8) I≠VI**, IV≠VI*
WC (cm) 105 (97–118) 106 (97–120) 105.5 (94.3-119) 102 (96–110.5) 110 (98–120) 103 (98–115.8) 104 (97–116) ns
Smoking history % 27.3 26.9 20.3 14.8 25.8 33.9 32.6 ***
SBP (mmHg) 130 (120–140) 130 (120–140) 130 (120–140) 130 (120–140) 130 (120–140) 130 (120–145) 130 (120–140) ns
DBP (mmHg) 80 (70–80) 80 (70–80) 80 (70–80) 70 (70–80) 80 (70–80) 70 (70–80) 80 (70–80) ns
TC (mg/dl) 178 (151–210) 183 (157–212) 201 (175–221) 176 (153–204) 162 (132–193) 179 (156–212) 165 (135–196) I≠IV,VI***, II≠IV,VI***
HDL-C (mg/dl) 45 (38–55) 47 (39–57) 49 (39–58) 47 (41–60) 42 (35–50) 45 (39–55) 43 (35–52) I≠IV*,I≠VI***, III≠IV,VI*
LDL-C (mg/dl) 102(77–131) 105(83–133) 121(99–144) 101(76–129) 82 (64–116) 102(74–130) 91 (70–123) I≠IV,VI***, II≠IV,VI***
TG (mg/dl) 124 (91–166) 123 (91–161) 125 (96–173) 117 (82–149) 126 (94–184) 123 (90–170) 130 (91–176) ns
HbA1c (%) 8.1 (7–9.5) 8.1 (7.1-9.7) 8 (6.9-10.2) 8.2 (6.8-9.5) 8.1 (7.2-9.5) 7.7 (6.8-9) 8 (7–9.3) ns
FPG (mg/dl) 174 (139–224) 174 (138–230) 177 (148–232) 169 (138–213) 182 (142–222) 177 (140–218) 174 (137–219) ns
2h-BG (mg/dl) 201 (160–265) 203 (160–270) 219 (174–286) 195 (160–232) 205 (160–270) 200 (167–239) 200 (155–254) ns
ΔBG (prandial) 34 (−6-76) 35 (−3-79) 44 (14–81) 39 (−8-88) 38 (−1-61) 31 (−22-58) 22 (−16-69) ns
MetS % 88 83.1 91.3 88.9 89 94.9 95.7 ***
3-4 MetS factors % 61 55.7 62.3 64.2 73 69.5 66.7 ***
eGFR 84 (65–101) 89 (74–106) 87 (61–100) 79 (65–99) 82 (57–103) 66 (49–88) 68 (50–88) I≠III*,V,VI***, II≠V*, II≠VI**, IV≠VI*
Albuminuria % 25.9 24.3 21.9 25.3 31.8 33.3 27.2 ns
DR % 37.3 28.6 33.3 40.7 38.2 78 49.2 ***
DN % 49.7 39.0 42.0 53.1 43.8 88.1 70.5 ***
Statin users % 65 55.4 69.6 70.4 76.4 81.4 78.7 ***
AH user % 80.4 72.3 79.7 85.2 91 96.6 91.9 ***
OHA users % 38.3 43.2 49.3 42 39.3 20.3 25.6 ***
OHA+BI users % 13.6 16.5 11.6 8.6 10.1 10.1 10.5 ***
MDI users % 48.1 48.1 39.1 49.4 50.6 69.3 63.9 ***
Data are medians (IQR, 25th–75th quartiles) or proportions; aKruskal-Wallis one-way ANOVA with Dunn’s multiple comparison post-hoc test and χ2-test; ns, not significant; *p<0.05, **p≤0.01, *** p≤0.001; 2h-BG, 2h
















Figure 1 Panel A: Macrovascular complication prevalence in our population. Panel B: Macrovascular subgroup prevalence in patients
with macrovascular complications. The data are frequencies.
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subjects.Multivariate Analysis
Multivariate logistic regression analysis was used to deter-
mine whether traditional cardiovascular risk factors (sex,
age, smoking status, diabetes duration, WC, SBP, DBP,
LDL-C levels, HDL-C levels, triglyceride levels, HbA1c
levels, FPG levels, use of antihypertensive and lipid-
lowering drugs and the presence of AHA/NHLBI-defined
metabolic syndrome) were associated with prevalent CVD
(dependent variable, MVD; reference group, NMVD),and
the data were expressed as odds ratios (ORs) (see Table 2).Figure 2 MetS prevalence (white columns) and “severity” (black colum
subgroups. The data are frequencies. *, significant at p ≤ 0.001 from Chi-SIn this analysis, in all of the macrovascular groups except
for the CAD and NSCS groups, age was significantly asso-
ciated with macrovascular disease. Male sex and diabetes
duration were significantly associated only in the PAD and
PVD groups. Reduced HDL-C was independently asso-
ciated in the CAD and PVD groups. Statin utilisation was
independently associated in all of the macrovascular
groups with the exception of the NCSC group. MetS
diagnosis was independently associated with only the PVD
group. In the logistic regression model, the inclusion of
logarithmically transformed values of HDL-C, LDL-C and
triglycerides did not change the results. Similarly, when
excluding MetS, logistic model coefficients were almost
unchanged (data not shown).ns) (presence of 3 or 4 AHA/NHLBI classification criteria) in the
quare test.
Table 2 Multivariable logistic regression analyses
NSCS CBVD CAD PAD PVD
OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p OR 95% CI p
Gender (male) 1.03 0.54–1.96 0.94 1.35 0.70–2.61 0.37 1.53 0.85–2.74 0.16 2.90 1.37–6.12 0.005 2.39 1.53–3.73 0.0001
Age 1.03 1.0–1.06 0.09 1.10 1.06–1.14 <0.0001 1.02 0.99–1.04 0.28 1.09 1.05–1.14 <0.0001 1.11 1.08–1.14 <0.0001
WC 0.99 0.97–1.01 0.36 0.97 0.95–0.99 0.01 0.99 0.98–1.01 0.45 0.98 0.96–1.00 0.07 0.99 0.97–1.00 0.04
Diabetes duration 0.98 0.94–1.01 0.17 0.99 0.96–1.02 0.68 1.01 0.98–1.04 0.60 1.05 1.02–1.08 0.004 1.04 1.02–1.06 0.0001
Smoking History (yes) 1.81 0.52–6.38 0.35 1.44 0.35–5.9 0.62 0.70 0.26–1–90 0.49 2.02 0.63–6.43 0.24 0.85 0.42–1.73 0.65
SBP 1.02 0.99–1.04 0.18 1.01 0.98–1.03 0.46 0.97 0.94–0.99 0.007 1.03 1.01–1.06 0.01 0.99 0.98–1.01 0.73
DBP 0.98 0.94–1.02 0.41 0.99 0.95–1.04 0.84 1.05 1.01–1.10 0.009 0.95 0.91–0.99 0.03 1.01 0.98–1.04 0.75
AH user (yes) 0.96 0.45–2.02 0.91 1.25 0.53–2.94 0.61 2.93 1.19–7.23 0.02 8.4 1.02–68.4 0.04 1,55 0.83–2.89 0.17
HDL-C 0.99 0.97–1.02 0.66 0.99 0.97–1.02 0.74 0.97 0.95–0.99 0.03 0.97 0.95–1.00 0.06 0.98 0.97–0.99 0.03
LDL-C 1.00 0.99–1.01 0.16 1.00 0.99–1.01 0.41 0.99 0.98–0.99 0.02 1.00 0.99–1.01 0.66 1.00 0.99–1.00 0.09
Triglycerides 1.00 0.99–1.00 0.45 0.99 0.99–1.00 0.18 1.00 0.99–1.00 0.70 1.00 0.99–1.01 0.65 1.00 0.99–1.00 0.48
Statin users (yes) 1.51 0.80–2.85 0.21 4.11 1.94–8.60 0.0002 2.31 1.24–4.30 0.009 4.92 1.99–12.10 0.0006 3.42 2.13–5.47 <0.0001
HbA1c 0.94 0.76–1.15 0.53 1.08 0.87–1.34 0.48 0.93 0.76–1.13 0.45 0.78 0.60–1.03 0.09 0.98 0.84–1.13 0.75
FPG 1.00 0.99–1.01 0.26 0.99 0.99–1.00 0.35 1.00 0.99–1.01 0.33 1.00 1.00–1.01 0.51 1.00 0.99–1.00 0.95
MetS (yes) 1.29 0.47–3.57 0.62 1.33 0.43–4.12 0.62 1.10 0.37–3.27 0.86 1.81 0.34–9.73 0.49 2.30 1.01–5.29 0.04
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The first goal of our study was to assess the prevalence of
different macroangiopathic conditions in our patients.
Our study demonstrates that 46.4% of our patient popula-
tion has macrovascular disease. It is well known that CVD
prevalence, incidence, and mortality are strikingly greater
in the diabetic than in the non-diabetic population.
According to the World Health Organization, CVD
prevalence in diabetic patients ranges from 26 to 36% [6].
The significantly higher prevalence of macrovascular
complications in our patients is likely linked to patient
characteristics (average age, diabetes duration, poor gly-
caemic control over time) and due to our inclusion of
NSCS patients. As expected, almost half of our patients
had polydistrectual involvement.
Advanced atherosclerotic vascular changes are often
preceded by impairment of endothelium-dependent
vasodilation, vascular smooth muscle dysfunction and
increased arterial stiffness. Today all of these factors are
recognized as predictors of vascular dysfunction in T2DM
patients [7]. Atherosclerotic disease usually causes sys-
temic involvement, which is more frequent in the diabetic
population [8]. Moreover, atherosclerosis in diabetic
patients is different from that in non-diabetic subjects
because both pathologic studies and angiographic reports
in individuals with coronary heart disease and PAD have
shown that diabetic patients have more blood vessels
involved, with a more diffuse atherosclerotic lesion distri-
bution [9,10].
Genetic studies have also shown that different macro-
vascular phenotypes (as CAD and CBVD) and T2DM
share a major linkage at the chromosome 12q24 locus. In
this regard, the gene of proteasome modulator 9 (PSMD9)
is linked to macrovascular pathology of T2DM [11].
Estimated twenty years incidence of different cardiovas-
cular complication phenotypes (ischaemic heart, myo-
cardial infarction, heart failure, cerebrovascular disease,
amputation of lower limbs) was evaluated in a Mexican
diabetic population by a simulation model indicating that
a large portion of this diabetic population is at risk of
myocardial infarction and cerebrovascolar disease in sub-
sequent years [12]. Also in our study, among patients with
macrovascular-isolated events, the majority of patients
were placed in the CAD (16%) and CBVD (14.6%) groups.
PAD, CAD and CBVD risk factors are similar and are
also typical atherosclerosis risk factors. These risk factors
include smoking, dyslipidaemia, diabetes and hyperten-
sion. However, specific risk factors, such as genetic back-
ground, could be more important for the development of
macro-vascular disease at certain sites. To the best of our
knowledge, no study has compared the anthropometric,
clinical and laboratory features in type 2 diabetic patients
by stratifying patients according to the type of macrovas-
cular involvement. For this reason, as a second studytarget, we tested the hypothesis that different macrovascu-
lar involvement types might correspond to different phe-
notypes. By analysing the anthropometric and clinical
characteristics of subgroups of patients, we found that
PAD and PVD patients were older, had had diabetes for a
longer period of time, were more likely to have been smo-
kers and had a lower weight, BMI and WC than did the
patients in the other groups. A multivariate analysis de-
monstrated that age, male sex, diabetes duration and the
use of statins were the most important independent PAD
and PVD risk factors. It is noteworthy that the same char-
acteristics were not found to be independent risk factors
in the CAD group and that the average patient age in this
group was comparable to that of the population without
macrovascular complications. The question arises of
whether a genetically determined predisposition alone
may explain the early onset of cardiac involvement in the
CAD group. In recent years, many genetic risk factors for
both diabetes and coronary artery disease have been
discovered through genome-wide association studies.
Genetic aspects of diabetes, diabetic macrovascular com-
plications and CAD may share mechanisms, leading to a
common effector hypothesis. However, only a few genetic
risk factors could be identified that modulate the risk for
both conditions. Polymorphisms in the TCF7L2 and near
the CDKNZA/B genes may be of great importance for
CAD development because these genes modulate both
conditions and are not necessarily related to hyperinsuli-
naemia or hyperglycaemia [13].
The complex interactions between genetic and environ-
mental factors on cardiometabolic risk were analyzed by
twin studies indicating that some cardiometabolic risk
factors had strong heritability (as weight, waist circumfer-
ence, SBP, DBP) while others were substantially influenced
by environmental factors [14].
By analysing glico-metabolic parameters (HbA1c, fasting
glucose, postprandial glucose and Δ post-preprandial blood
glucose) we found no differences among the six subgroups.
Despite a clear association between diabetes and athero-
sclerotic vascular disease, the underlying mechanism
responsible for the two diseases is not fully understood.
The relative importance of “non-glycaemic” risk factors
and hyperglycemia “per sè” has always been debated [15].
Results on the causal relationship between hyperglycemia
and macroangiopathy have been contradictory. Plenty of
evidence suggest a significative relationship between HbA1c
levels, post-prandial hyperglycemia, and risk of CV events
and adverse outcomes especially in overweight and obese
patients [16,17] . However, recently three major studies,
ACCORD [18], ADVANCE [19] and VADT [20] eva-
luated the impact of attaining euglycemia (ACCORD) or
near-euglycemia (ADVANCE and VADT) in patients with
long-lasting diabetes and high cardio-vascular risk. None
of these studies, either individually or on pooled analysis,
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mortality, although a meta-analysis revealed a 15-17%
reduction in the incidence of non-fatal myocardial infarc-
tion in those patients exposed to tight glucose control
[21]. A higher mortality was observed in the intensive glu-
cose control arm of ACCORD, leading to the premature
termination of the glucose-lowering component of this
study. The weak association between glycemic control
and macro-vascular disease observed in UKPDS [22] has
been confirmed and amplified by these recent interven-
tion studies. Accordingly, our data show that glycated
hemoglobin, post-prandial and fasting glucose were similar
in each subgroup considered. However, the relationship
between hyperglycemia and macrovascular complications
is made even more complex by the potential role of epi-
genetic mechanisms, as the metabolic memory, by which
a prior exposure to hyperglycemia predisposes diabetic
patients to the continuing development of vascular diseases
despite a subsequent good glycemic control [23]. Further-
more, in our study, referral bias (diabetic patients with poor
metabolic control referred to us for the first time) did not
allow to clarify the causal or temporal relationship among
macrovascular events and glycemic control over time.
By analysing the lipid profile, we found a clear differ-
ence in HDL-C among the groups, which was lower in
CAD, PAD, and PVD patients. These data are in accord-
ance with other scientific evidence that support the im-
portance of this macroangiopathy-associated risk factor.
In a multivariate analysis, we also confirmed that reduced
HDL-C values are independent CAD and PVD risk fac-
tors (the association was borderline significant for the
PAD group). The importance of HDL-C as “target the-
rapy” is now emerging from recent cardiovascular trials
of CETP (cholesteryl ester transfer protein) inhibitors,
such as Anacetrapib [24] and Evacetrapib [25]. This new
pharmacological group is very promising for cardiovascu-
lar risk reduction either when administered alone or in
conjunction with conventional therapy.
Many reports have suggested that metabolic syndrome
may precede/predict vascular disease. It has been reported
that insulin resistance and metabolic syndrome increase
the risk of new cardiovascular events also in patients with-
out known diabetes but with manifest arterial disease [26].
In type 2 diabetes, metabolic syndrome is highly prevalent
and often precedes hyperglycaemia onset [27,28]. Further-
more, insulin resistance and metabolic syndrome predict
atherosclerosis in type 2 diabetic patients [29]. Our find-
ings support the clinical relevance of MetS component
detection, which may be a simple, quick tool to stratify
diabetic patients according to the expected macrovascular
complication severity (as a polydistrectual disease).
Microvascular complications were not equally present
in the various groups. We found more diabetic nephro-
pathy, as assessed by micro/macroalbuminuria or bycalculating the eGFR in the CAD, PAD and PVD groups.
Diabetic neuropathy was more frequent in the PAD and
PVD groups, and diabetic retinopathy was strikingly
present in the PAD group. As expected, patients in the
CAD, PAD and PVD groups were the largest statin and
antihypertensive drug users, and those in the PAD and
PVD groups were more frequently treated with multiple
insulin injections.
Strengths and limitations
Macrovascular complication phenotyping in type 2 dia-
betic patients has not yet been reported. Such phenotyp-
ing may have diagnostic and therapeutic implications in
type 2 diabetes management. An additional strength of
our study is the large number of patients who were stu-
died in a single clinical centre, with each diagnostic
examination being performed by a single operator. How-
ever, we recognise that there are some limitations to our
study. First, the retrospective cross-sectional design pre-
cluded the establishment of causal or temporal relations
among macrovascular events and other features in our
diabetic population. In addition, this study mainly
included older diabetic subjects who had unsatisfactory
glycaemic control, who may not have been representa-
tive of the general diabetic population.
Conclusion
Our study shows that nearly half of diabetic patients, espe-
cially those who are elderly and male with a long disease
duration, have polydistrectual atherosclerotic involvement.
The characterization of different phenotypes may have
a clinical significance for the everyday clinician.
Firstly, different factors were associated with isolated
coronary artery disease, like a mean age comparable to that
of patients without macro-vascular complications and a
high frequency of severe metabolic syndrome. These data
raise the interesting hypothesis that coronary artery dis-
ease, metabolic syndrome and diabetes may be genetically
linked in some individuals. Further studies may clarify
whether this is because of genetic background and/or be-
cause coronary heart disease might be the first event in
polydistrectual atherosclerotic involvement.
Secondly, low HDL-C values are a marker of PAD, CAD
and PVD, confirming the importance of HDL-C as a
potential therapeutic target. Alternatively, lifestyle modifi-
cation strategies to prevent a low HDL-cholesterol should
be implemented.
Abbreviations
ABI: Ankle-brachial index; ACS: Acute coronary syndrome; BMI: Body mass
index; CAD: Coronary artery disease; CAS: Carotid artery stenting;
CBVD: Cerebrovascular disease; CEA: Carotid endarterectomy; CLI: Critical
limb ischaemia; CT: Computed tomography; CTA: Computed tomography
angiography; CVD: Cardiovascular disease; DBP: Diastolic blood pressure;
DUS: Duplex ultrasonography; eGFR: Estimated glomerular filtration rate;
FPG: Fasting plasma glucose; MVD: Macrovascular disease; MDIs: Multiple
Papa et al. Cardiovascular Diabetology 2013, 12:20 Page 9 of 9
http://www.cardiab.com/content/12/1/20daily injections; MetS: Metabolic syndrome; NMVD: No macrovascular disease;
NSCS: Non-significant carotid stenosis; PAD: Peripheral artery diseases;
PTA: Percutaneous transluminal angioplasty; PVD: Polyvascular disease;
SBP: Systolic blood pressure; TcPO2: Transcutaneuos oxygen pressure;
T2DM: Type 2 diabetes mellitus; TIA: Transient ischaemic attack; WC: Waist
circumference.
Competing interests
None of the authors has any conflict of interest.
Authors’ contributions
GP participated in the overall design, data collection, statistical analysis, data
interpretation, writing and critical review of the manuscript. CD, MPI, CL, RM
participated in data collection, data interpretation and critically revised the
manuscript before final approval. CF supervised the design and conduction
of the study, participated in data interpretation and critically revised the
manuscript before final approval. All authors read and approved the final
manuscript.
Acknowledgments
We thank Dr. V. Pezzino for critical review of the manuscript. We thank Dr. F.
Palermo for his advice on the statistical analysis.
Received: 6 December 2012 Accepted: 16 January 2013
Published: 18 January 2013
References
1. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M: Mortality from
coronary heart disease in subjects with type 2 diabetes and in
nondiabetic subjects with and without prior myocardial infarction.
N Engl J Med 1999, 339:229–234.
2. Brun E, Nelson NG, Bennett PH, Imperatore G, Zoppini G, Verlato G, et al:
Verona Diabetes Study. Diabetes duration and cause-specific mortality in
the Verona Diabetes Study. Diabetes Care 2000, 23:1119–1123.
3. American Diabetes Association: Economic costs of diabetes in the U.S.
in 2007. Diabetes Care 2008, 31(3):596–615.
4. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA,
et al: Harmonizing the Metabolic Syndrome: a Joint Interim Statement of
the International Diabetes Federation Task Force on Epidemiology and
Prevention; National Heart, Lung, and Blood Institute; American Heart
Association; World Heart Federation; International Atherosclerosis
Society; and International Association for the Study of Obesity.
Circulation 2009, 120:1640–1645.
5. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D: A more accurate
method to estimate glomerular filtration rate from serum creatinine:
A new prediction equation. Modification of Diet in Renal Disease Study
Group. Ann Intern Med 1999, 130:461–470.
6. Morrish NJ, Wang SL, Stevens LK, Fuller JH, Keen H: Mortality and causes of
death in the WHO multinational study of vascular disease in diabetes.
Diabetologia 2001, 44(Suppl 2):S14–S21.
7. Naka KK, Papathanassiou K, Bechlioulis A, Kazakos N, Pappas K, Tigas S,
Makriyiannis D, Tsatsoulis A, Michalis LK: Determinants of vascular function
in patients with type 2 diabetes. Cardiovasc Diabetol 2012, 11:127.
doi:10.1186/1475-2840-11-127.
8. Beckman JA, Creager MA, Libby P: Diabetes and atherosclerosis:
epidemiology, patophysiology, and management. JAMA 2002, 287:2570–2581.
9. Waller BF, Palumbo PJ, Lie JT, Roberts WC: Status of the coronary arteries
at necropsy in diabetes mellitus with onset after age 30 years: analysis
of 229 diabetic patients with and without clinical evidence of coronary
heart disease and comparison to 183 control subjects. Am J Med 1980,
69:498–506.
10. Conrad MC: Large and small artery occlusion in diabetics and
nondiabetics with severe vascular disease. Circulation 1967, 36:83–91.
11. Gragnoli C: Proteasome modulator 9 and macrovascular pathology of
T2D. Cardiovasc Diabetol 2011, 10:32. doi:10.1186/1475-2840-10-32.
12. Reynoso-Noveron N, Mehta R, Almeda-Valdes P, Rojas-Martinez R,
Villalpando S, Hernandez-Avila M, Aquilar-Salinas CA: Estimated incidence
of cardiovascular complications related to type 2 diabetes in Mexico
using the UKPDS outcome model and a population-based survey.
Cardiovasc Diabetol 2011, 10:1. doi:10.1186/1475-2840-10-1.13. Sousa AG, Selvatici L, Krieger JE, Pereira AC: Association between genetics of
diabetes, coronary artery disease, and macrovascular complications:
exploring a common ground hypothesis. Rev Diabet Stud 2011, 8(2):230–244.
14. Jermendy G, Horvath T, Littvay L, Steinbach R, Jermendy AL, Tarnoki AD,
Tarnoki DL, Metneki J, Osztovits J: Effect of genetic and environmental
influences on cardiometabolic risk factors: a twin study. Cardiovasc
Diabetol 2011, 10:96. doi:10.1186/1475-2840-10-96.
15. Milicevic Z, Raz I, Beattie BD, Campaigne BN, Sarwat S, Gromniak E,
Kowalska I, Galic E, Tan M, Hanefeld M: Natural History of Cardiovascular
Disease in Pazients with diabetes. Diabetes Care 2008, 31(2):S155–S160.
doi:10.2337/dc08-s240.
16. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K,
Hanefeld M: Postchallenge plasma glucose and glycemic spikes are more
strongly associated with atherosclerosis than fasting glucose or HbA1c
level. Diabetes Care 2000, 23:1830–1934.
17. Andersson C, van Gaal L, Caterson ID, Weeke P, James WP, Coutinho W,
Finer N, Sharma AM, Maggiori AP, Torp-Pedersen C: Relationship between
HbA1c levels and risk of cardiovascular adverse outcomes and all-cause
mortality in overweight and obese cardiovascular high-risk women and
men with type 2 diabetes. Diabetologia 2012, 55(9):2348–2355.
doi:10.1007/s00125-012-2584-3.
18. Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group,
Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, et al: Effects of
intensive glucose lowering in type 2 diabetes. N Engl J Med 2008,
358(24):2545–2559.
19. ADVANCE Collaborative Group, Patel A, MacMahon S, Chalmers J, Neal B,
Billot L, et al: Intensive blood glucose and vascular outcomes in patients
with type 2 diabetes. N Engl J Med 2008, 358(24):2560–2572.
20. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al:
Glucose control and vascular complications in veterans with type 2
diabetes. N Engl J Med 2009, 360(2):129–139.
21. Ray KK, Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Preiss D,
Erqou S, Sattar N: Effect of intensive control of glucose on cardiovascular
outcomes and death in patients with diabetes mellitus: a meta-analysis
of randomized controlled trials. Lancet 2009, 23(9677):1765–1772.
22. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose
control with sulphonylureas or insulin compared with conventional
treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998, 352(9131):837–853.
23. Reddy MA, Natarajan R: Role of epigenetic mechanisms in the vascular
complications of diabetes. Subcell Biochem 2012, 61:435–454.
doi:10.1007/978-94-007-4525-4_19.
24. Gurfinkel R, Joy TR: Anacetrapib: hope for CETP inhibitors? Cardiovasc Ther
2011, 29(5):327–339. doi:10.1111/j.1755-5922.2010.00142.x.
25. Nicholls SJ, Brewer HB, Kastelein JJ, Krueger KA, Wang MD, Shao M, et al:
Effects of the CETP inhibitor evacetrapib administered as monotherapy or
in combination with statins on HDL and LDL cholesterol: a randomized
controlled trial. JAMA 2011, 306(19):2099–2109.
26. Verhagen SN, Wassinik AM, van der Graaf Y, Gorter PM, Visseren FL, SMART
Study Group: Insulin resistance increases the occurrence of new
cardiovascular events in patients with manifest arterial disease without
know diabetes. The SMART study. Cardiovasc Diabetol 2011, 10:100.
doi:10.1186/1475-2840-10-100.
27. Bonora E, Targher G, Formentini G, Calcaterra F, Lombardi S, Marini F, et al:
The metabolic syndrome is an independent predictor of cardiovascular
disease in type 2 diabetic subjects: prospective data from the Verona
Diabetes Complications Study. Diabet Med 2004, 21:52–58.
28. Alexander CM, Landsman PB, Teutsch SM, Haffner SM: NCEP-defined
metabolic syndrome, diabetes, and prevalence of coronary heart disease
among NHANES III participants age 50 years and older. Diabetes 2003,
52:1210–1214.
29. Bonora E, Formentini G, Calcaterra F, Lombardi S, Marini F, Zenari L, et al:
HOMA-estimated insulin resistance is an independent predictor of
cardiovascular disease in type 2 diabetic subjects: prospective data from
the Verona Diabetes Complication Study. Diabetes Care 2002, 25:1135–1141.
doi:10.1186/1475-2840-12-20
Cite this article as: Papa et al.: Macrovascular complication phenotypes
in type 2 diabetic patients. Cardiovascular Diabetology 2013 12:20.
